The higher-dose semaglutide formulation for obesity (Wegovy, 2.4 mg weekly) can produce 10-15% weight loss, while diabetes doses typically yield more modest reductions
According to MedPage Today, 10-15% of patients do not respond adequately to semaglutide, though for many others, the issue isn't non-response but diminished response over time
This prolonged presence is actually beneficial for treatment adherence, as it allows for once-weekly dosing rather than daily injections
This is why muscle building gets harder with age
Sam An, a pharmacist at a compounding pharmacy until 2021, told me that his workplace employed about twenty peoplepharmacists, technicians, cashiers, couriersin what resembled a chemistry laboratory